GPRC5D缺失增强骨髓瘤细胞增殖能力与竞争适应性
该研究通过OPM-2细胞模型模拟GPRC5D单等位与双等位缺失,发现单等位缺失降低表面抗原表达并导致抗GPRC5D治疗耐药;完全缺失则改变转录状态和磷酸化蛋白信号网络,形成促增殖趋化因子环境,提高基础增殖速率,从而获得竞争优势。
要点
- GPRC5D单等位缺失降低表面表达并导致抗GPRC5D治疗耐药。
- GPRC5D完全缺失重编程磷酸化蛋白网络,促进增殖性趋化因子环境。
- GPRC5D缺失赋予骨髓瘤细胞竞争优势,抗GPRC5D治疗可能筛选出侵袭表型。
核心结论
- GPRC5D缺失增强骨髓瘤细胞增殖能力与竞争适应性,并可能被抗GPRC5D免疫治疗筛选放大。
研究设计与样本
- 在OPM-2细胞中模拟GPRC5D单等位与双等位缺失,研究其对骨髓瘤细胞生物学及对GPRC5D靶向免疫治疗反应的影响。
主要发现
- OPM-2细胞中GPRC5D单等位缺失降低表面抗原表达并赋予对GPRC5D靶向治疗的耐药性。
- GPRC5D完全缺失改变骨髓瘤细胞转录状态,重编程磷酸化蛋白信号网络,形成促增殖的趋化因子环境。
- GPRC5D缺失提高骨髓瘤细胞基础增殖速率,提供竞争性优势,并可能通过抗GPRC5D治疗筛选侵袭表型而放大。
临床怎么用
- 接受抗GPRC5D免疫治疗的患者需关注GPRC5D表达缺失或下调,其可能导致耐药并筛选出增殖优势克隆。
局限性
- 研究仅基于OPM-2细胞模型,结论需在临床样本和体内模型中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapies targeting surface antigens have transformed the treatment landscape of multiple myeloma (MM), with GPRC5D emerging as a promising therapeutic target. Monoallelic loss of GPRC5D is frequently observed in newly diagnosed MM patients, and the incidence of acquired GPRC5D alterations increases following exposure to GPRC5D-directed therapies. However, the functional consequences of both baseline monoallelic and therapy-induced biallelic GPRC5D alterations remain poorly understood. In this study, we modeled monoallelic versus biallelic loss of GPRC5D to investigate their impact on MM cell biology and responsiveness to GPRC5D-targeted immunotherapies. Our results demonstrate that monoallelic GPRC5D loss in OPM-2 cells reduces surface expression of the antigen and confers resistance to GPRC5D-directed therapies. Complete loss of GPRC5D alters the transcriptional state of MM cells and promotes reprogramming of the phosphoproteomic circuitry ultimately resulting in a pro-proliferative chemokine environment. As a result, GPRC5D deficiency increases the basal proliferation rate of MM cells thereby providing a competitive advantage which may further be amplified by selecting these aggressive phenotypes during ongoing treatment with anti-GPRC5D immunotherapies.
引用
- Munawar U, Thurner J, Nerreter S, et al. Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy. Leukemia. 2026. PMID: 41917280. doi:10.1038/s41375-026-02920-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。